Real-world outcomes in patients with malignancy and moderate-severe psoriasis treated with guselkumab

The treatment of psoriasis in patients with a personal history of cancer is a matter of debate and limited evidence is available to guide clinicians. The objective is to report a multicentre real-life experience of a group of patients with psoriasis undergoing treatment with Guselkumab and a history of cancer. Methods We conducted a multi-center retrospective Spanish study enrolling patients with moderate-to-severe plaque psoriasis and neoplasia being treated with Guselkumab for their psoriasis. Results Twenty patients with moderate-to-severe psoriasis and at least 12 weeks of ongoing treatment were included. For the analysis, a 52 week follow-up period was evaluated in terms of efficacy and safety. Most of the malignancies in these patients were solid tumours. The percentage of patients achieving PASI ≤ 3 at week 12 and week 52 was 80% and 87,5%, respectively, while 68,8% of patients achieved PASI ≤1. A 52-week survival rate of 100% in the study population was observed (n=20), including those patients with concomitant active cancers (n=14). No adverse effects or dropouts related to guselkumab safety profile were detected. Conclusion Guselkumab not only demonstrates high efficacy in treating psoriasis but also exhibits a favorable safety profile in patients with neoplasms.